GLP-1 & compounded medication availability in California (2026)

California is OrderlyMeds’ biggest market and one of the most closely watched states for compounding oversight. All four of our core lines ship here. The detail worth your time is not whether medication arrives. It is what California asks of the pharmacies doing the shipping, which changed twice in the past fourteen months.

Conditional state

Availability facts last reviewed: November 16, 2026

Line-by-line availability for California

Availability of all ten OrderlyMeds product lines in California, with typical delivery times and notes
Product lineAvailable in California?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Our highest-volume state for this line.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days Identical pricing to every other state.
NAD+ Yes 8–10 business days Fulfilled by licensed partner pharmacies.
Sermorelin Yes 8–10 business days Standard online ordering flow.
Glutathione No N/A Not something OrderlyMeds carries right now.
BPC-157 Yes 8–10 business days Carried as a compounded injectable. Section below.
TB-500 Yes 8–10 business days In our catalog as a compounded injectable; see below.
KPV No N/A We don’t offer this line, injectables only.
Epitalon Yes 8–10 business days Offered as a compounded injectable; federal facts below.
MOTS-c Yes 8–10 business days Dispensed as a compounded injectable; see its own federal record below.

California availability was last reviewed November 16, 2026. Rows we cannot honestly fill are shown as gaps, not hidden. That is the point of this page.

BPC-157, TB-500, KPV, Epitalon & MOTS-c for California residents

OrderlyMeds sells four of these five peptides in California, as it does in every state we serve: BPC-157, TB-500, Epitalon and MOTS-c, each compounded as an injectable. KPV we do not sell anywhere, because our peptide lines are injectables and KPV is not compounded as one. Because interest in all five is real, each section below carries that line’s own two cited federal facts: FDA’s safety-risk position on it and the compounding pathway that currently covers it. Read both, because either one alone is half the story, and that holds for the four lines we ship exactly as it does for the one we do not. The five records are not interchangeable, so each is cited separately.

BPC-157 in California

OrderlyMeds carries BPC-157 for California addresses as a compounded injectable, filled by a licensed partner pharmacy under a patient-specific prescription.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in California

Californians can order TB-500 from us as a compounded injectable, dispensed under a patient-specific prescription.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in California

KPV is outside our formulary, in California as everywhere, because our peptide lines are compounded as injectables and KPV is not.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in California

We dispense Epitalon to California addresses as a compounded injectable, under a patient-specific prescription.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in California

We dispense MOTS-c to California addresses as a compounded injectable. Its federal record, below, is specific to this line and does not match the four above it.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What California’s pharmacy regulators say about compounded medications

California does not block telehealth-prescribed compounded medications. It raises the bar for the pharmacies supplying them. Two recent changes reshaped how out-of-state pharmacies serve California patients, and both are about accountability rather than access.

The board adopted updated compounding regulations effective October 2025, tightening requirements for compounded drug preparations dispensed to California patients. Source: California State Board of Pharmacy.

As of July 2026, nonresident pharmacies shipping into California must designate a pharmacist-in-charge holding a California license, alongside existing nonresident pharmacy licensure. Source: California State Board of Pharmacy.

California permits prescribing on the basis of an appropriate telehealth examination under the state's telehealth standard of care. Source: Center for Connected Health Policy (CCHP) Policy Finder.

For a California order, the patient-facing path is unchanged: eligibility check, provider evaluation, pharmacy fulfillment, tracked delivery. What changed sits behind the scenes: the pharmacies serving California carry state-specific obligations, which is what you should want from the country’s largest market. Pricing stays national: a California ZIP code pays the same flat price as every other state, at every dose.

California availability FAQs

Can I get compounded GLP-1s in California?

Yes. Compounded semaglutide and compounded tirzepatide both ship to California addresses through OrderlyMeds’ licensed pharmacy network, from $74/month for new semaglutide customers.

Did California’s 2025 compounding rules stop compounded medications?

No. They changed what is required of pharmacies, not whether patients can receive compounded medications. The cited specifics are in the regulator section above.

Does OrderlyMeds ship research peptides like BPC-157 to California?

Four of the five, yes. We carry BPC-157, TB-500, Epitalon and MOTS-c as compounded injectables, California included. KPV we do not carry in any state. Each line’s current federal status, including FDA’s safety position on it, is stated in full above for all five.

How fast is delivery to California?

The published window is 8–10 business days from signup, tracking included.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone